[Triclabendazole].

C, Boulliat; A, Wolf; K, Gaillard; M, Oliver

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2012

Data sources: Europe PubMed Central

[Triclabendazole].

descriptionPublicationkeyboard_double_arrow_right Article 05 Apr 2012 French Journal:Medecine tropicale : revue du Corps de sante colonial, volume 70 (issn: 0025-682X,

Copyright policy )

Authors: C, Boulliat; A, Wolf; K, Gaillard; M, Oliver;

pmid: 22368929

[Triclabendazole].

- Summary
- Subjects
- Metrics

Abstract

Triclabendazole is indicated for treatment of human fascioliasis, a widespread disease. Treatment is straightforward and generally well tolerated. However, increasing resistance to this therapy has been observed since the 1990s. Research is being carried out to develop new medications with special interest in artesunate.

Keywords

Anthelmintics, Fascioliasis, Humans, Benzimidazoles, Triclabendazole

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average